We report on overall survival and valve‐related outcomes after bioprosthetic valve replacement in prior transplant recipients. From January 2004 to December 2018, 20 consecutive patients (mean age 65.7‐years, 90% male) with prior non‐cardiac tra...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=O136022972
2019년
-
0902-0063
1399-0012
SCI;SCIE;SCOPUS
학술저널
n/a-n/a [※수록면이 p5 이하이면, Review, Columns, Editor's Note, Abstract 등일 경우가 있습니다.]
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
We report on overall survival and valve‐related outcomes after bioprosthetic valve replacement in prior transplant recipients. From January 2004 to December 2018, 20 consecutive patients (mean age 65.7‐years, 90% male) with prior non‐cardiac tra...
We report on overall survival and valve‐related outcomes after bioprosthetic valve replacement in prior transplant recipients.
From January 2004 to December 2018, 20 consecutive patients (mean age 65.7‐years, 90% male) with prior non‐cardiac transplantation underwent bioprosthetic aortic (n = 18) or combined aortic and mitral (n = 2) valve replacement. Patients consisted of kidney (n = 14), lung (n = 2), liver (n = 3), and bone‐marrow (n = 2) transplants with the most common indication for valve replacement being calcific degeneration (n = 12). Outcomes were measured over a 12‐year span, with a median follow‐up duration of 3.9 years.
Overall survival at 30 days was 100% and at median follow‐up was 60%. Acute kidney injury occurred in 50% (n = 10) with temporary dialysis required in 5% (n = 1) and 15% (n = 3) suffered respiratory failure. No patients experienced major bleeding, heart failure, or sternal wound infection. No patients required redo valve replacement during the study period.
Our results provide contemporary data demonstrating that patients with prior transplant can undergo bioprosthetic valve replacement with acceptable inhospital mortality rates and long‐term survival, with a low rate of major morbidity. Furthermore, bioprosthetic valve replacement is a viable option in this group of patients with no redo valve replacement and acceptable long‐term hemodynamic valvular function.
Depressive symptoms, physical activity, and clinical events: The ADAPT prospective pilot study